These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 1521828)

  • 41. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization.
    Arocha-Piñango CL; Rodriguez S; Nagy H; Perez Requejo JL
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):561-5. PubMed ID: 2133234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
    Soya K; Takezawa Y; Terasawa F; Okumura N
    Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abnormal polymerization and normal binding of plasminogen and t-PA in three new dysfibrinogenaemias: Barcelona III and IV (gamma Arg 275-->His) and Villajoyosa (gamma Arg 275-->Cys).
    Borrell M; Garí M; Coll I; Vallvé C; Tirado I; Soria JM; Sala N; Muñoz C; Oliver A; García A
    Blood Coagul Fibrinolysis; 1995 May; 6(3):198-206. PubMed ID: 7654933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrinogen Stony Brook II: partial characterization of a heterozygously transmitted peptide A anomaly.
    Galanakis DK; Hultin M
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):567-70. PubMed ID: 2133235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterozygous abnormal fibrinogen Osaka III with the replacement of gamma arginine-275 by histidine has an apparently higher molecular weight gamma-chain variant.
    Yoshida N; Imaoka S; Hirata H; Matsuda M; Asakura S
    Thromb Haemost; 1992 Nov; 68(5):534-8. PubMed ID: 1455400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
    Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
    Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two novel mutations in the fibrinogen γ nodule.
    Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
    Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
    Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
    Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibrinogen Matsumoto II: gamma 308 Asn-->Lys (AAT-->AAG) mutation associated with bleeding tendency.
    Okumura N; Furihata K; Terasawa F; Ishikawa S; Ueno I; Katsuyama T
    Br J Haematol; 1996 Sep; 94(3):526-8. PubMed ID: 8790154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acquired coagulation inhibitor delaying fibrinopeptide release.
    Marciniak E; Greenwood MF
    Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'.
    Vorjohann S; Fish RJ; Biron-Andréani C; Nagaswami C; Weisel JW; Boulot P; Reyftmann L; de Moerloose P; Neerman-Arbez M
    Thromb Haemost; 2010 Nov; 104(5):990-7. PubMed ID: 20806111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia.
    Reber P; Furlan M; Henschen A; Kaudewitz H; Barbui T; Hilgard P; Nenci GG; Berrettini M; Beck EA
    Thromb Haemost; 1986 Dec; 56(3):401-6. PubMed ID: 3563970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibrinogens Kosai and Ogasa: Bbeta15Gly-->Cys (GGT-->TGT) substitution associated with impairment of fibrinopeptide B release and lateral aggregation.
    Hirota-Kawadobora M; Terasawa F; Yonekawa O; Sahara N; Shimizu E; Okumura N; Katsuyama T; Shigematsu H
    J Thromb Haemost; 2003 Feb; 1(2):275-83. PubMed ID: 12871501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.
    Andes WA; Chavin SI; Beltran G; Stuckey WJ
    Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of delayed fibrinopeptide-A release on fibrin structure. Studies of an abnormal fibrinogen.
    Carr ME; Qureshi GD
    J Biol Chem; 1987 Nov; 262(32):15568-74. PubMed ID: 3680212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
    Ebert RF; Bell WR
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
    Schreiber WE; Schmer G
    Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.